Effects of a New Botanical Extracts Combination on Quality of Life in Menopausal Spanish Women

NCT ID: NCT04381026

Last Updated: 2020-05-08

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

57 participants

Study Classification

INTERVENTIONAL

Study Start Date

2017-04-19

Study Completion Date

2018-07-10

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study was designed to evaluate the beneficial effects and safety of a standardised botanical extract combination containing soy isoflavone extract, grains of paradise seed dry extract and pomegranate skin dry extract on health-related Quality of Life in healthy Spanish menopausal women with hot flashes, anxiety, and depressive symptoms using the self reported and validated Cervantes Scale.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Fifty-seven outpatient women (45-65 years) with menstrual problems associated with climacteric syndrome were enrolled from April 2018 to April 2019 in the context of a prospective, placebo-controlled, double-blind study. Women were randomized to receive treatment with either the botanical combination (250 mg daily divided into two doses) or placebo for eight weeks. At the beginning and end of the study, health-related Quality of Life was assessed using the Cervantes Scale.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Menopause Dietary Supplements Quality of Life

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

TRIPLE

Participants Caregivers Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Placebo Group

Pill of 500 mg containing filler agent, two pills daily for eight weeks.

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DIETARY_SUPPLEMENT

Filler agent

Treatment Group with botanical extracts

Pill of 500 mg containing botanicals and filler agent, two pills daily for eight weeks.

Group Type EXPERIMENTAL

Botanical dry extracts combination

Intervention Type DIETARY_SUPPLEMENT

Aframomum melgueta dry extract (50mg), Glycine max bean dry extract (100mg) and Punica granatum skin extract (100mg)

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Botanical dry extracts combination

Aframomum melgueta dry extract (50mg), Glycine max bean dry extract (100mg) and Punica granatum skin extract (100mg)

Intervention Type DIETARY_SUPPLEMENT

Placebo

Filler agent

Intervention Type DIETARY_SUPPLEMENT

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Women in the Climacteric Phase under medical criteria based on Health questionnaire, Blood and urine test.
* Informed consent to participate in the study.

Exclusion Criteria

* Hormone-related pathologies.
* Menopause from surgery origin.
* Family or personal history of endocrine cancer.
* Known hypersensitivity to gluten, soybeans, soy protein, dairy products, pomegranate or grains of paradise.
* Vegetarian diet or daily consumption of soya rich-products during the last year.
* Anovulatory treatment.
* Hormone replacement treatment.
Minimum Eligible Age

45 Years

Maximum Eligible Age

55 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Clínica Barem

UNKNOWN

Sponsor Role collaborator

Nektium Pharma SL

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Laura López-Ríos, PhD

Role: PRINCIPAL_INVESTIGATOR

Nektium Pharma SL

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Clinica Barem

Las Palmas de Gran Canaria, Las Palmas (Canary Islands), Spain

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Spain

References

Explore related publications, articles, or registry entries linked to this study.

Greene JG. Constructing a standard climacteric scale. Maturitas. 1998 May 20;29(1):25-31. doi: 10.1016/s0378-5122(98)00025-5.

Reference Type RESULT
PMID: 9643514 (View on PubMed)

Buendia Bermejo J, Rodriguez Segarra R, Yubero Bascunana N, Martinez Vizcaino V. [Design and validation of a questionnaire in Spanish for measuring the quality of life in postmenopausal women: the MENCAV questionnaire]. Aten Primaria. 2001 Feb 15;27(2):94-100. doi: 10.1016/s0212-6567(01)78780-x. Spanish.

Reference Type RESULT
PMID: 11256098 (View on PubMed)

Palacios S, Ferrer-Barriendos J, Parrilla JJ, Castelo-Branco C, Manubens M, Alberich X, Marti A; Grupo Cervantes. [Health-related quality of life in the Spanish women through and beyond menopause. Development and validation of the Cervantes Scale]. Med Clin (Barc). 2004 Feb 21;122(6):205-11. doi: 10.1016/s0025-7753(04)74198-6. Spanish.

Reference Type RESULT
PMID: 15012887 (View on PubMed)

Heinemann K, Ruebig A, Potthoff P, Schneider HP, Strelow F, Heinemann LA, Do MT. The Menopause Rating Scale (MRS) scale: a methodological review. Health Qual Life Outcomes. 2004 Sep 2;2:45. doi: 10.1186/1477-7525-2-45.

Reference Type RESULT
PMID: 15345062 (View on PubMed)

Low Dog T. Menopause: a review of botanical dietary supplements. Am J Med. 2005 Dec 19;118 Suppl 12B:98-108. doi: 10.1016/j.amjmed.2005.09.044.

Reference Type RESULT
PMID: 16414334 (View on PubMed)

Tranche S, Brotons C, Pascual de la Pisa B, Macias R, Hevia E, Marzo-Castillejo M. Impact of a soy drink on climacteric symptoms: an open-label, crossover, randomized clinical trial. Gynecol Endocrinol. 2016 Jun;32(6):477-82. doi: 10.3109/09513590.2015.1132305. Epub 2016 Jan 25.

Reference Type RESULT
PMID: 26806546 (View on PubMed)

Kang SJ, Choi BR, Kim SH, Yi HY, Park HR, Kim DC, Choi SH, Han CH, Park SJ, Song CH, Ku SK, Lee YJ. Dried pomegranate potentiates anti-osteoporotic and anti-obesity activities of red clover dry extracts in ovariectomized rats. Nutrients. 2015 Apr 9;7(4):2622-47. doi: 10.3390/nu7042622.

Reference Type RESULT
PMID: 25912038 (View on PubMed)

Balk E, Chung M, Chew P, Ip S, Raman G, Kupelnick B, Tatsioni A, Sun Y, Wolk B, DeVine D, Lau J. Effects of soy on health outcomes. Evid Rep Technol Assess (Summ). 2005 Aug;(126):1-8. doi: 10.1037/e439502005-001. No abstract available.

Reference Type RESULT
PMID: 16194125 (View on PubMed)

Ferrari A. Soy extract phytoestrogens with high dose of isoflavones for menopausal symptoms. J Obstet Gynaecol Res. 2009 Dec;35(6):1083-90. doi: 10.1111/j.1447-0756.2009.01058.x.

Reference Type RESULT
PMID: 20025635 (View on PubMed)

Klein MA, Nahin RL, Messina MJ, Rader JI, Thompson LU, Badger TM, Dwyer JT, Kim YS, Pontzer CH, Starke-Reed PE, Weaver CM. Guidance from an NIH workshop on designing, implementing, and reporting clinical studies of soy interventions. J Nutr. 2010 Jun;140(6):1192S-1204S. doi: 10.3945/jn.110.121830. Epub 2010 Apr 14.

Reference Type RESULT
PMID: 20392880 (View on PubMed)

Munro IC, Harwood M, Hlywka JJ, Stephen AM, Doull J, Flamm WG, Adlercreutz H. Soy isoflavones: a safety review. Nutr Rev. 2003 Jan;61(1):1-33. doi: 10.1301/nr.2003.janr.1-33.

Reference Type RESULT
PMID: 12638461 (View on PubMed)

Satpathy S, Patra A, Purohit AP. Estrogenic activity of Punica granatum L. peel extract. Asian Pacific J. Reprod. 2013; 2(1): 19-24

Reference Type RESULT

Bialonska D, Ramnani P, Kasimsetty SG, Muntha KR, Gibson GR, Ferreira D. The influence of pomegranate by-product and punicalagins on selected groups of human intestinal microbiota. Int J Food Microbiol. 2010 Jun 15;140(2-3):175-82. doi: 10.1016/j.ijfoodmicro.2010.03.038. Epub 2010 Apr 2.

Reference Type RESULT
PMID: 20452076 (View on PubMed)

Mori-Okamoto J, Otawara-Hamamoto Y, Yamato H, Yoshimura H. Pomegranate extract improves a depressive state and bone properties in menopausal syndrome model ovariectomized mice. J Ethnopharmacol. 2004 May;92(1):93-101. doi: 10.1016/j.jep.2004.02.006.

Reference Type RESULT
PMID: 15099854 (View on PubMed)

Ilic NM, Dey M, Poulev AA, Logendra S, Kuhn PE, Raskin I. Anti-inflammatory activity of grains of paradise (Aframomum melegueta Schum) extract. J Agric Food Chem. 2014 Oct 29;62(43):10452-7. doi: 10.1021/jf5026086. Epub 2014 Oct 20.

Reference Type RESULT
PMID: 25293633 (View on PubMed)

Sugita J, Yoneshiro T, Hatano T, Aita S, Ikemoto T, Uchiwa H, Iwanaga T, Kameya T, Kawai Y, Saito M. Grains of paradise (Aframomum melegueta) extract activates brown adipose tissue and increases whole-body energy expenditure in men. Br J Nutr. 2013 Aug;110(4):733-8. doi: 10.1017/S0007114512005715. Epub 2013 Jan 11.

Reference Type RESULT
PMID: 23308394 (View on PubMed)

Igwe SA, Emeruwa IC, Modie JA. Ocular toxicity of Afromomum melegueta (alligator pepper) on healthy Igbos of Nigeria. J Ethnopharmacol. 1999 Jun;65(3):203-6. doi: 10.1016/s0378-8741(98)00188-3.

Reference Type RESULT
PMID: 10404417 (View on PubMed)

Lopez-Rios L, Barber MA, Wiebe J, Machin RP, Vega-Morales T, Chirino R. Influence of a new botanical combination on quality of life in menopausal Spanish women: Results of a randomized, placebo-controlled pilot study. PLoS One. 2021 Jul 21;16(7):e0255015. doi: 10.1371/journal.pone.0255015. eCollection 2021.

Reference Type DERIVED
PMID: 34288973 (View on PubMed)

Related Links

Access external resources that provide additional context or updates about the study.

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

PRO_WH_HCT_2016.01

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Effects of Soy Isoflavones on Menopausal Hot Flashes
NCT00179556 COMPLETED PHASE2/PHASE3